| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c1d7583f1931f6b8065de4ae62bc52cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e10a90707bd61bd48fa0b368746c664
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eea837d4973e84ec854b922c7d423c1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa93c22cb07b784848bfc0ef68fef6ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d6c314a1ab59c006a10d998e461f735 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 |
| filingDate |
2014-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05c328e689110f4c51534f9f7e21b0e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b49c7812f1ff509a8ad7700f37cd4bb8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c5c33e41150447782f47972cfad8fc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aef9fbed04237675994749fd1dd5018b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7637048006a6fa95102c133376030ba2 |
| publicationDate |
2014-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014204859-A2 |
| titleOfInvention |
Bcl6 inhibitors as anticancer agents |
| abstract |
The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (bric a brac, tramtrack, broad complex / pox virus zinc finger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involved oncogene in diffuse large B-cell lymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice. DLBCLs are aggressive tumors that arise from germinal center (GC) B- cells and are the most common form of non-Hodgkin's lymphomas. BCL6 is required for survival of DLBCL cells and can limit their ability to respond to DNA damaging agents. It is also frequently expressed in follicular lymphomas (FLs), and may be required for survival of these tumors as well. DLBCL and FL collectively constitute ∼60-70% of B-cell lymphomas and the incidence of these tumors has been rising in recent decades. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021001567-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11390580-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11512095-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4108240-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108456205-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3638649-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11414378-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9943506-B2 |
| priorityDate |
2013-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |